These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
163 related articles for article (PubMed ID: 10910095)
1. Oncogenic transformation of cells by a conditionally active form of the protein kinase Akt/PKB. Mirza AM; Kohn AD; Roth RA; McMahon M Cell Growth Differ; 2000 Jun; 11(6):279-92. PubMed ID: 10910095 [TBL] [Abstract][Full Text] [Related]
2. Cooperative regulation of the cell division cycle by the protein kinases RAF and AKT. Mirza AM; Gysin S; Malek N; Nakayama K; Roberts JM; McMahon M Mol Cell Biol; 2004 Dec; 24(24):10868-81. PubMed ID: 15572689 [TBL] [Abstract][Full Text] [Related]
3. CD28 costimulation mediates down-regulation of p27kip1 and cell cycle progression by activation of the PI3K/PKB signaling pathway in primary human T cells. Appleman LJ; van Puijenbroek AA; Shu KM; Nadler LM; Boussiotis VA J Immunol; 2002 Mar; 168(6):2729-36. PubMed ID: 11884439 [TBL] [Abstract][Full Text] [Related]
4. Requirement for the PI3K/Akt pathway in MEK1-mediated growth and prevention of apoptosis: identification of an Achilles heel in leukemia. Blalock WL; Navolanic PM; Steelman LS; Shelton JG; Moye PW; Lee JT; Franklin RA; Mirza A; McMahon M; White MK; McCubrey JA Leukemia; 2003 Jun; 17(6):1058-67. PubMed ID: 12764369 [TBL] [Abstract][Full Text] [Related]
5. Induction of cell proliferation in quiescent NIH 3T3 cells by oncogenic c-Raf-1. Kerkhoff E; Rapp UR Mol Cell Biol; 1997 May; 17(5):2576-86. PubMed ID: 9111327 [TBL] [Abstract][Full Text] [Related]
6. Ability of the activated PI3K/Akt oncoproteins to synergize with MEK1 and induce cell cycle progression and abrogate the cytokine-dependence of hematopoietic cells. Shelton JG; Blalock WL; White ER; Steelman LS; McCubrey JA Cell Cycle; 2004 Apr; 3(4):503-12. PubMed ID: 15004527 [TBL] [Abstract][Full Text] [Related]
7. PKB/Akt mediates cell-cycle progression by phosphorylation of p27(Kip1) at threonine 157 and modulation of its cellular localization. Shin I; Yakes FM; Rojo F; Shin NY; Bakin AV; Baselga J; Arteaga CL Nat Med; 2002 Oct; 8(10):1145-52. PubMed ID: 12244301 [TBL] [Abstract][Full Text] [Related]
9. Effects of oncogenic ErbB2 on G1 cell cycle regulators in breast tumour cells. Neve RM; Sutterlüty H; Pullen N; Lane HA; Daly JM; Krek W; Hynes NE Oncogene; 2000 Mar; 19(13):1647-56. PubMed ID: 10763821 [TBL] [Abstract][Full Text] [Related]
10. PKB/Akt phosphorylates p27, impairs nuclear import of p27 and opposes p27-mediated G1 arrest. Liang J; Zubovitz J; Petrocelli T; Kotchetkov R; Connor MK; Han K; Lee JH; Ciarallo S; Catzavelos C; Beniston R; Franssen E; Slingerland JM Nat Med; 2002 Oct; 8(10):1153-60. PubMed ID: 12244302 [TBL] [Abstract][Full Text] [Related]
11. Epigallocatechin-3-gallate inhibits epidermal growth factor receptor signaling pathway. Evidence for direct inhibition of ERK1/2 and AKT kinases. Sah JF; Balasubramanian S; Eckert RL; Rorke EA J Biol Chem; 2004 Mar; 279(13):12755-62. PubMed ID: 14701854 [TBL] [Abstract][Full Text] [Related]
12. Activated Raf-1 causes growth arrest in human small cell lung cancer cells. Ravi RK; Weber E; McMahon M; Williams JR; Baylin S; Mal A; Harter ML; Dillehay LE; Claudio PP; Giordano A; Nelkin BD; Mabry M J Clin Invest; 1998 Jan; 101(1):153-9. PubMed ID: 9421477 [TBL] [Abstract][Full Text] [Related]
13. Differential effects of kinase cascade inhibitors on neoplastic and cytokine-mediated cell proliferation. Shelton JG; Moye PW; Steelman LS; Blalock WL; Lee JT; Franklin RA; McMahon M; McCubrey JA Leukemia; 2003 Sep; 17(9):1765-82. PubMed ID: 12970777 [TBL] [Abstract][Full Text] [Related]
14. Sustained activation of the raf-MEK-ERK pathway elicits cytokine unresponsiveness in T cells. Chen D; Heath V; O'Garra A; Johnston J; McMahon M J Immunol; 1999 Dec; 163(11):5796-805. PubMed ID: 10570262 [TBL] [Abstract][Full Text] [Related]
15. Interferon-gamma inhibits hepatocyte growth factor-stimulated cell proliferation of human bronchial epithelial cells: upregulation of p27(kip1) cyclin-dependent kinase inhibitor. Takami K; Takuwa N; Okazaki H; Kobayashi M; Ohtoshi T; Kawasaki S; Dohi M; Yamamoto K; Nakamura T; Tanaka M; Nakahara K; Takuwa Y; Takizawa H Am J Respir Cell Mol Biol; 2002 Feb; 26(2):231-8. PubMed ID: 11804875 [TBL] [Abstract][Full Text] [Related]
16. Reversal of the Ras-induced transformed phenotype by HR12, a novel ras farnesylation inhibitor, is mediated by the Mek/Erk pathway. Reuveni H; Geiger T; Geiger B; Levitzki A J Cell Biol; 2000 Dec; 151(6):1179-92. PubMed ID: 11121434 [TBL] [Abstract][Full Text] [Related]
17. The cell survival signal Akt is differentially activated by PDGF-BB, EGF, and FGF-2 in osteoblastic cells. Chaudhary LR; Hruska KA J Cell Biochem; 2001 Mar; 81(2):304-11. PubMed ID: 11241670 [TBL] [Abstract][Full Text] [Related]
18. YC-1-inhibited proliferation of rat mesangial cells through suppression of cyclin D1-independent of cGMP pathway and partially reversed by p38 MAPK inhibitor. Chiang WC; Teng CM; Lin SL; Chen YM; Tsai TJ; Hsieh BS Eur J Pharmacol; 2005 Jul; 517(1-2):1-10. PubMed ID: 15950964 [TBL] [Abstract][Full Text] [Related]
19. Chemical genetic blockade of transformation reveals dependence on aberrant oncogenic signaling. Fan QW; Zhang C; Shokat KM; Weiss WA Curr Biol; 2002 Aug; 12(16):1386-94. PubMed ID: 12194819 [TBL] [Abstract][Full Text] [Related]
20. Pharmacologic inhibition of RAF-->MEK-->ERK signaling elicits pancreatic cancer cell cycle arrest through induced expression of p27Kip1. Gysin S; Lee SH; Dean NM; McMahon M Cancer Res; 2005 Jun; 65(11):4870-80. PubMed ID: 15930308 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]